These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 6233250)

  • 1. In-vitro studies with ciprofloxacin, a new 4-quinolone compound.
    Reeves DS; Bywater MJ; Holt HA; White LO
    J Antimicrob Chemother; 1984 Apr; 13(4):333-46. PubMed ID: 6233250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The in-vitro activity of ciprofloxacin compared with that of norfloxacin and nalidixic acid.
    King A; Shannon K; Phillips I
    J Antimicrob Chemother; 1984 Apr; 13(4):325-31. PubMed ID: 6233249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid.
    Bauernfeind A; Petermüller C
    Eur J Clin Microbiol; 1983 Apr; 2(2):111-5. PubMed ID: 6222896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria.
    Chin NX; Neu HC
    Antimicrob Agents Chemother; 1984 Mar; 25(3):319-26. PubMed ID: 6232895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The comparative in-vitro activity of eight newer quinolones and nalidixic acid.
    King A; Phillips I
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():1-20. PubMed ID: 3468100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative activities of ciprofloxacin (Bay o 9867), norfloxacin, pipemidic acid, and nalidixic acid.
    Muytjens HL; van der Ros-van de Repe J; van Veldhuizen G
    Antimicrob Agents Chemother; 1983 Aug; 24(2):302-4. PubMed ID: 6227281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The comparative in-vitro activity of pefloxacin.
    King A; Phillips I
    J Antimicrob Chemother; 1986 Apr; 17 Suppl B():1-10. PubMed ID: 2940213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative in vitro activity of three new quinolone antibiotics against recent clinical isolates.
    Forsgren A
    Scand J Infect Dis; 1985; 17(1):91-4. PubMed ID: 3158070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative antimicrobial activity of enoxacin, ciprofloxacin, amifloxacin, norfloxacin and ofloxacin against 177 bacterial isolates.
    Bassey CM; Baltch AL; Smith RP
    J Antimicrob Chemother; 1986 May; 17(5):623-8. PubMed ID: 2941401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of the new 4-quinolone compound Ro 23-6240.
    Clarke AM; Zemcov SJ
    Eur J Clin Microbiol; 1987 Apr; 6(2):161-4. PubMed ID: 3109895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The comparative in-vitro activity of norfloxacin, ciprofloxacin, enoxacin and nalidixic acid against 423 strains of gram-negative rods and staphylococci isolated from infected hospitalised patients.
    Guimaraes MA; Noone P
    J Antimicrob Chemother; 1986 Jan; 17(1):63-7. PubMed ID: 2936708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A laboratory assessment of ciprofloxacin and comparable antimicrobial agents.
    Shrire L; Saunders J; Traynor R; Koornhof HJ
    Eur J Clin Microbiol; 1984 Aug; 3(4):328-32. PubMed ID: 6237900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.
    Wise R; Andrews JM; Edwards LJ
    Antimicrob Agents Chemother; 1983 Apr; 23(4):559-64. PubMed ID: 6222695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of ciprofloxacin (Bay o 9867).
    Fass RJ
    Antimicrob Agents Chemother; 1983 Oct; 24(4):568-74. PubMed ID: 6228192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-vitro activity of pefloxacin compared to enoxacin, norfloxacin, gentamicin and new beta-lactams.
    Clarke AM; Zemcov SJ; Campbell ME
    J Antimicrob Chemother; 1985 Jan; 15(1):39-44. PubMed ID: 3156112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The in-vitro activity of CI-934 compared with that of other new 4-quinolones and nalidixic acid.
    King A; Shannon K; Slegg J; Phillips I
    J Antimicrob Chemother; 1986 Aug; 18(2):163-9. PubMed ID: 3463557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of pefloxacin compared to that of quinolones and other antimicrobial agents.
    Neu HC; Chin NX; Labthavikul P; Saha G
    Chemioterapia; 1984 Aug; 3(4):235-41. PubMed ID: 6241847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incomplete cross-resistance of nalidixic and pipemidic acid-resistant variants of Serratia marcescens against ciprofloxacin, enoxacin, and norfloxacin.
    Traub WH
    Chemotherapy; 1985; 31(1):34-9. PubMed ID: 3156026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative in vitro activity of five quinoline derivatives and five other antimicrobial agents used in oral therapy.
    Hoogkamp-Korstanje JA
    Eur J Clin Microbiol; 1984 Aug; 3(4):333-8. PubMed ID: 6237901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The in vitro and in vivo activity of ciprofloxacin.
    Zeiler HJ; Grohe K
    Eur J Clin Microbiol; 1984 Aug; 3(4):339-43. PubMed ID: 6237902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.